- Recommendation ID
- NG33/3
- Question
For isoniazid-resistant TB, what is the most effective regimen for reducing mortality and
morbidity?- Any explanatory notes
(if applicable) Why this is important
There is little evidence for the treatment of isoniazid resistant TB. This is the most common form of drug resistance in the UK, occurring in 7.5% of TB cases. Currently, treatment is not always
successful, even when the recommended drugs are given for the recommended time and there are no adherence issues. It is particularly difficult to treat if there are treatment interruptions or if the
central nervous system is involved. Randomised controlled trials are needed to compare different anti-TB regimens for isoniazid-resistant TB, assessing mortality, treatment success or treatment
failure, rates of relapse and adverse events.
Source guidance details
- Comes from guidance
- Tuberculosis
- Number
- NG33
- Date issued
- January 2016
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 30/09/2019 |